Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 5/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MLNR | O43193 | 2/20 | 0.39 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | F10 | P00742 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13097637 | 0.89 | CYP2D6 (0.60) | CYP2D6PDE3BPDE3A | |
| SCHEMBL13097645 | 0.88 | CYP2D6 (0.53) | CYP2D6PDE3BPDE3AMEN1KMT2A | |
| SCHEMBL13097646 | 0.87 | CYP2D6 (0.56) | CYP2D6PDE3BPDE3AMLNR | |
| SCHEMBL13097647 | 0.86 | CYP2D6 (0.46) | CYP2D6KMT2A | |
| SCHEMBL3095845 | 0.80 | CYP2D6 (0.72) | CYP2D6PDE3BPDE3AF10MEN1 | |
| SCHEMBL13097639 | 0.77 | CYP2D6 (0.66) | CYP2D6PDE3BPDE3A | |
| SCHEMBL13097649 | 0.77 | CYP2D6 (0.55) | CYP2D6GAA | |
| SCHEMBL13097570 | 0.77 | CYP2D6 (0.79) | CYP2D6PDE3BPDE3AGAA | |
| SCHEMBL13097640 | 0.76 | CYP2D6 (0.69) | CYP2D6PDE3BPDE3A | |
| SCHEMBL13097614 | 0.76 | CYP2D6 (0.54) | CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-8367702-B2 | Quinolone derivative | ASTELLAS PHARMA INC. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| US-20100256113-A1 | QUINOLONE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-10-07 | — | — | US | disclosed |
| EP-2194044-A1 | QUINOLONE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256113-A1 | QUINOLONE DERIVATIVE | NQO1, NQO2, NADK | CYP2D6 230/4885PDE3B 1554/4885PDE3A 2484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.